Please provide your email address to receive an email when new articles are posted on . Researchers from The Children’s Hospital of Philadelphia have identified risk factors for early and late ...

Melissa Lyle, MD: Hello, everyone. I am Melissa Lyle, cardiology fellow at Mayo Clinic. Today, we will be discussing the management of Fontan patients. I am joined by my colleagues, Dr Alexander Egbe ...

Please provide your email address to receive an email when new articles are posted on . For the two-part UNIVERSE study, 12 children who underwent the Fontan procedure were enrolled in a single-arm ...

PHILADELPHIA — In a phase 3 study, the phosphodiesterase-5 (PDE-5) inhibitor udenafil (Mezzion Pharma) did not improve the primary end point of oxygen consumption at peak exercise, but was associated ...

The letter by Asrani et al. (May 2 issue) 1 reports cases of hepatocellular carcinoma in patients who have undergone Fontan palliation for univentricular hearts. Our practice includes yearly screening ...

The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure. New data were announced from a phase 3 ...

A multi-center study has identified critical risk factors that increase the likelihood of death in children with a heart defect who are awaiting or have recently undergone heart transplantation, ...

SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, Inc. (Mezzion) announced that its confirmatory Phase 3 FUEL-2 study evaluating JURVIGO® (udenafil) 1 in adolescents and young ...